MTDH and neoplasm: AEG-1 levels did not correlate with median overall survival, type of relapse, clinical stage, tumor grade, surgical stage, percentage or residual EAC or lymphovascular invasion and the authors suggested that AEG-1 may not serve as a prognostic marker in resistant EAC after therapy [74].